2014 News Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014
12/23/14J.P. Morgan Healthcare Conference
Posted on 23 December, 2014 33rd Annual J.P. Morgan Healthcare Conference, San Francisco January 12-15, 2015... 
Printer Friendly Version
11/03/14Protein & Antibody Engineering Summit
Posted on 3 November, 2014  Merus to present at the annual Protein & Antibody Engineering Summit (PEGS), Lisbon on November 4, 2014.... 
Printer Friendly Version
09/18/14Patent position of Merus’ MeMo® Mouse strengthened by ruling of European Patent Office
Posted on 18 September, 2014 In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013, thereby requesting revocation of the patent.“This outcome fully confirms our firm belief that we have freedom to operate for our MeMo® mice for common light chain therapeutic human antibodies,” said To... 
Printer Friendly Version
03/04/14ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
Posted on 4 March, 2014 Under the terms of the agreement, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX® technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead products, a bispecific anti-cancer antibody. The license is covering clinical development and production. Financial details have not been disclosed.The GlymaxX® technology for the production of afucosylated antibodies and proteins is based on the stable integrati... 
Printer Friendly Version

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts